1Isaka S, Sawai K, Tomiie M, et al. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in cervical intraepithelial neoplasia [J]. Int J Oncol, 2002, 21(2): 281-287.
2Imazano Y, Takebayashi Y, Nishiyama K, et al. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma [J]. J Clin Oncol, 1997, 15(7):2570-2578.
3Takebayashi Y, Akiyama S, Akiba S, et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma [J]. J Natl CancerInst, 1996, 88(16): 1110-1117.
4Saito H, Tsujitani S, Oka S, et al. The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma [J]. Br J Cancer, 1999, 81 (3): 484-489.
5Saito S, Tsuno N, Nagawa H, et al. Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma [J]. Cancer, 2000, 88(1):42-49.
6Marchetti S, Chazal M, Dubreull A, et al. Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis [J]. Br J Cancer, 2001, 85 (3): 439-445.
7Fromowitz FB, Viola MV, Chao S, et al. ras p21 Expression in the progression of breast cancer [J]. Hum Pathol, 1987, 18(12):1268-1275.
8Koukourakis MI, Giatromanolaki A, Kakolyris S, et al. Different pathems of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival [J]. Br J Cancer, 1998, 77(10):1696-1703.
9Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue [J]. Eur J Cancer, 1998,34(8):1274 -1281.
10Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients [J]. Cancer Chemother Pharmacol, 2000, 45(4):291-297.
4Kenji Omura. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines[J] 2003,International Journal of Clinical Oncology(3):132～138
